Category - Developments

Developments

CellAegis Devices begins U.S. pivotal trial of autoRIC device

Closely-held CellAegis Devices has enrolled the first patients in a U.S. pivotal trial of its autoRIC device, which automatically delivers remote ischemic conditioning (RIC) to provide a non-invasive, cardio-protective...

April 10, 2018

Developments

Ortho RTi posts positive Ortho-R data in rotator cuff repair

Ortho Regenerative Technologies (CSE:ORTH) reported positive preliminary MRI outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries. Conducted by researchers from...

April 2, 2018

Developments

BioLight completes first stage of sale of IOPtima

BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) has completed the first stage of the investment in and acquisition in stages of its subsidiary, IOPtima, by Chengdu Kanghong Pharmaceutical Group of China. Under the first...

March 29, 2018

Developments

Molteni acquires Titan Pharma’s European Probuphine IP

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a definitive asset purchase, supply and support agreement with closely-held L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, through which...

March 22, 2018

Developments

Vital Therapies completes enrollment in VTL-308 pivotal trial

Vital Therapies’ (NASDAQ:VTL) VTL-308 Phase 3 trial to evaluate its cell-based therapy, ELAD, in subjects with severe alcoholic hepatitis has reached its enrollment target of 150 subjects. Subjects in VTL-308 were...

March 22, 2018

Developments

Scientus Pharma gains media awareneness

A Canadian Press piece appearing in several newspapers and broadcast news reports features closely-held Scientus Pharma and other companies as they look beyond legalization of recreational cannabis this summer to...

March 16, 2018

Developments

Ortho RTi gets European patent allowance protecting Ortho-R technology

Ortho Regenerative Technologies (CSE:ORTH) has received a notice of allowance from the European Patent Office that when issued, will provide intellectual property protection for the composition of matter of its Ortho-R...

March 8, 2018

Developments

Profound Medical upsizes bought deal financing from $20- to $30-million

Profound Medical (TSXV:PRN) has entered into an agreement with a syndicate of underwriters, led by Canaccord Genuity, to sell on a bought deal basis a total of 30 million units at a price of $1 each for gross proceeds...

February 28, 2018

Developments

VolitionRx reports positive interim Nu.Q diagnostic results in colorectal cancer

VolitionRx (NYSE American:VNRX) announced interim results from its first asymptomatic colorectal cancer (CRC) frontline screening study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark, with...

February 27, 2018

Developments

Micromedic’s CellDetect detects prostate cancer cells in urine

Micromedic Technologies (TASE: MCTC) announced successful results of a clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology. The study included 59 urine samples (28...

February 26, 2018

Category - Developments

Subscribe